Search results for "Luteal Cells"

showing 2 items of 2 documents

Dysregulated genes and their functional pathways in luteinized granulosa cells from PCOS patients after cabergoline treatment

2018

Polycystic ovarian syndrome (PCOS) is a common reproductive disorder frequently associated with a substantial risk factor for ovarian hyperstimulation syndrome (OHSS). Dopamine receptor 2 (D2) agonists, like cabergoline (Cb2), have been used to reduce the OHSS risk. However, lutein granulosa cells (LGCs) from PCOS patients treated with Cb2 still show a deregulated dopaminergic tone (decreased D2 expression and low dopamine production) and increased vascularization compared to non-PCOS LGCs. Therefore, to understand the PCOS ovarian physiology, it is important to explore the mechanisms that underlie syndrome based on the therapeutic effects of Cb2. Here, LGCs from non-PCOS and PCOS patients …

0301 basic medicineAdultEmbryologymedicine.medical_specialtyendocrine systemCabergolineendocrine system diseasesOvarian hyperstimulation syndromeAKT103 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineCabergolineLuteal CellsmedicineHumansErgolines030219 obstetrics & reproductive medicineGranulosa Cellsbusiness.industryDopaminergicOvaryObstetrics and Gynecologynutritional and metabolic diseasesCell Biologymedicine.diseasefemale genital diseases and pregnancy complicationsVascular endothelial growth factorVascular endothelial growth factor A030104 developmental biologyEndocrinologyReproductive MedicinechemistryGene Expression RegulationDopamine receptorDopaminergic synapseCase-Control StudiesDopamine AgonistsFemalebusinessTranscriptomeBiomarkersmedicine.drugPolycystic Ovary Syndrome
researchProduct

Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.

2007

Abstract Context: Ovarian hyperstimulation syndrome (OHSS) results from increased vascular permeability (VP) caused by ovarian hypersecretion of vascular endothelial growth factor (VEGF), which activates its receptor-2. In animals, the dopamine receptor 2 agonist cabergoline (Cb2) inactivates VEGF receptor-2 and prevents increased VP. Objective: Our objective was to test whether Cb2 reduces VP and prevents OHSS in humans. Design: We conducted a prospective, randomized, double-blind study on oocyte donors at risk of developing OHSS (>20 follicles, >12 mm developed, and >20 oocytes retrieved). Interventions: Cb2 0.5 mg/d (n = 37) or a placebo (n = 32) was administered fro…

Endocrinology Diabetes and MetabolismClinical BiochemistryOvarian hyperstimulation syndromeVascular permeabilityHematocritBiochemistrychemistry.chemical_compoundHemoglobinsEndocrinologyPregnancyAscitesImage Processing Computer-AssistedMedicineProspective Studiesmedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionObstetrics and GynecologyAscitesGeneral MedicineHemoconcentrationMagnetic Resonance ImagingVascular endothelial growth factorHematocritDopamine AgonistsFemalemedicine.symptommedicine.drugAgonistAdultmedicine.medical_specialtyCabergolinemedicine.drug_classContext (language use)Fertilization in VitroDopamine agonistOvarian Hyperstimulation SyndromeDouble-Blind MethodInternal medicineCabergolineLuteal CellsHumansErgolinesGranulosa Cellsbusiness.industryReceptors Dopamine D2Peritoneal fluidBiochemistry (medical)Ovarymedicine.diseaseEndocrinologychemistryRegional Blood FlowbusinessExtracellular SpaceThe Journal of clinical endocrinology and metabolism
researchProduct